Jamesi Novum

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Jamesi Novum (Metformin Hydrochloride, Sitagliptin)

Q: What is Jamesi Novum used for?

Jamesi Novum is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise when monotherapy does not achieve target glycemic levels.

Q: How does Metformin Hydrochloride work?

Metformin lowers blood sugar by decreasing hepatic glucose production and enhancing the sensitivity of muscle and fat cells to insulin, which helps the body use glucose more efficiently.

Q: What is the usual dose of Jamesi Novum?

The specific dose of Jamesi Novum is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Q: Is Jamesi Novum safe during pregnancy or breastfeeding?

Safety in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

Q: How do I order Jamesi Novum from GNH India?

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Q: How does Jamesi Novum compare with other antidiabetic options?

Jamesi Novum combines a biguanide (metformin) with a DPP‑4 inhibitor (sitagliptin), offering complementary mechanisms that can achieve better glycemic control than either agent alone, while generally having a lower risk of hypoglycemia compared with sulfonylureas.

Q: What are the storage requirements for Jamesi Novum?

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight, and heat to maintain product stability.

Q: How is Jamesi Novum administered?

Jamesi Novum is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew it.

Q: What are the most serious risks associated with Jamesi Novum?

Serious risks include lactic acidosis, especially in patients with renal or hepatic impairment, and pancreatitis. Patients should be educated to seek immediate medical attention for severe abdominal pain, unexplained fatigue, or rapid breathing.

Q: Who should not use Jamesi Novum?

Jamesi Novum is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with conditions predisposing to lactic acidosis such as acute heart failure or severe infection.

Metformin Hydrochloride and Sitagliptin, the active ingredients in Jamesi Novum, are a biguanide and a DPP‑4 inhibitor presented as an oral tablet for adult use. They treat type 2 diabetes mellitus in patients who need combined glucose‑lowering therapy.

GNH India supplies Jamesi Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Zentiva, K.S.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Jamesi Novum is indicated for type 2 diabetes mellitus, a chronic metabolic disorder that impairs glucose regulation.

Type 2 diabetes mellitus: improves overall glycemic control when used with diet and exercise.
Inadequate control on metformin alone: adds DPP‑4 inhibition to further lower HbA1c.
Adults requiring combined therapy: reduces fasting and post‑prandial glucose levels.

How It Works

Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, prolonging the activity of endogenous incretin hormones that stimulate glucose‑dependent insulin secretion and suppress glucagon release, together producing a complementary reduction in blood glucose.

Side Effects

Adverse reactions may occur with any antidiabetic regimen and should be monitored.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
Headache: mild to moderate intensity.
Mild hypoglycemia: especially when combined with insulin or sulfonylureas.

Serious or Rare Side Effects

Lactic acidosis: a rare but life‑threatening metabolic complication.
Pancreatitis: severe abdominal pain with elevated enzymes.
Severe allergic reactions: rash, angioedema, or anaphylaxis.
Hepatic dysfunction: elevated liver enzymes or jaundice.
Renal impairment: worsening kidney function may necessitate discontinuation.

Precautions & Warnings

Careful assessment and monitoring are required before and during therapy.

Renal function: evaluate eGFR before initiation and periodically thereafter.
Hepatic function: avoid in patients with severe hepatic impairment.
Lactic acidosis risk: contraindicated in conditions causing hypoxia or severe infection.
Pregnancy and lactation: use only if potential benefit justifies potential risk.
Drug interactions: review concomitant medications for possible additive effects.
Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Jamesi Novum may interact with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): increased metformin accumulation.
Strong CYP3A4 inhibitors (e.g., ketoconazole): raise sitagliptin plasma levels.
Concurrent sulfonylureas or insulin: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely)

Iodinated contrast agents: temporary discontinuation of metformin may be needed.
Diuretics: may affect renal clearance of metformin.
Beta‑blockers: can mask hypoglycemia symptoms, requiring closer glucose monitoring.

Frequently Asked Questions

Jamesi Novum is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise when monotherapy does not achieve target glycemic levels.

Metformin lowers blood sugar by decreasing hepatic glucose production and enhancing the sensitivity of muscle and fat cells to insulin, which helps the body use glucose more efficiently.

The specific dose of Jamesi Novum is determined by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety in pregnancy and lactation has not been fully established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Jamesi Novum combines a biguanide (metformin) with a DPP‑4 inhibitor (sitagliptin), offering complementary mechanisms that can achieve better glycemic control than either agent alone, while generally having a lower risk of hypoglycemia compared with sulfonylureas.

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight, and heat to maintain product stability.

Jamesi Novum is taken orally, usually once daily with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew it.

Serious risks include lactic acidosis, especially in patients with renal or hepatic impairment, and pancreatitis. Patients should be educated to seek immediate medical attention for severe abdominal pain, unexplained fatigue, or rapid breathing.

Jamesi Novum is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with conditions predisposing to lactic acidosis such as acute heart failure or severe infection.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 15 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.